These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 29192598)

  • 1. Personalized medicine, pharmacogenomic and companion biomarker.
    Manceau H; Amrani K; Peoc'h K
    Ann Biol Clin (Paris); 2017 Dec; 75(6):631-636. PubMed ID: 29192598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The emerging era of pharmacogenomics: current successes, future potential, and challenges.
    Lee JW; Aminkeng F; Bhavsar AP; Shaw K; Carleton BC; Hayden MR; Ross CJ
    Clin Genet; 2014 Jul; 86(1):21-8. PubMed ID: 24684508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenetics in Italy: current landscape and future prospects.
    Floris M; Moschella A; Alcalay M; Montella A; Tirelli M; Fontana L; Idda ML; ; Guarnieri P; Capasso M; Mammì C; Nicoletti P; Miozzo M
    Hum Genomics; 2024 Jul; 18(1):78. PubMed ID: 38987819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenetics of heart failure.
    Mestroni L; Begay RL; Graw SL; Taylor MR
    Curr Opin Cardiol; 2014 May; 29(3):227-34. PubMed ID: 24717669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Precision medicine and pharmacogenetics: what does oncology have that addiction medicine does not?
    Kranzler HR; Smith RV; Schnoll R; Moustafa A; Greenstreet-Akman E
    Addiction; 2017 Dec; 112(12):2086-2094. PubMed ID: 28431457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-Effectiveness of Pharmacogenomic and Pharmacogenetic Test-Guided Personalized Therapies: A Systematic Review of the Approved Active Substances for Personalized Medicine in Germany.
    Plöthner M; Ribbentrop D; Hartman JP; Frank M
    Adv Ther; 2016 Sep; 33(9):1461-80. PubMed ID: 27406232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenomic Biomarkers: an FDA Perspective on Utilization in Biological Product Labeling.
    Schuck RN; Grillo JA
    AAPS J; 2016 May; 18(3):573-7. PubMed ID: 26912182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrating rare genetic variants into pharmacogenetic drug response predictions.
    Ingelman-Sundberg M; Mkrtchian S; Zhou Y; Lauschke VM
    Hum Genomics; 2018 May; 12(1):26. PubMed ID: 29793534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Personalizing health care: feasibility and future implications.
    Godman B; Finlayson AE; Cheema PK; Zebedin-Brandl E; Gutiérrez-Ibarluzea I; Jones J; Malmström RE; Asola E; Baumgärtel C; Bennie M; Bishop I; Bucsics A; Campbell S; Diogene E; Ferrario A; Fürst J; Garuoliene K; Gomes M; Harris K; Haycox A; Herholz H; Hviding K; Jan S; Kalaba M; Kvalheim C; Laius O; Lööv SA; Malinowska K; Martin A; McCullagh L; Nilsson F; Paterson K; Schwabe U; Selke G; Sermet C; Simoens S; Tomek D; Vlahovic-Palcevski V; Voncina L; Wladysiuk M; van Woerkom M; Wong-Rieger D; Zara C; Ali R; Gustafsson LL
    BMC Med; 2013 Aug; 11():179. PubMed ID: 23941275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenetic Decision Support Tools: A New Paradigm for Late-Life Depression?
    Abbott R; Chang DD; Eyre HA; Bousman CA; Merrill DA; Lavretsky H
    Am J Geriatr Psychiatry; 2018 Feb; 26(2):125-133. PubMed ID: 29429869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PG-path: Modeling and personalizing pharmacogenomics-based pathways.
    Hong JY; Kim JH
    PLoS One; 2020; 15(5):e0230950. PubMed ID: 32365122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity.
    Lauschke VM; Zhou Y; Ingelman-Sundberg M
    Pharmacol Ther; 2019 May; 197():122-152. PubMed ID: 30677473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. APF2: an improved ensemble method for pharmacogenomic variant effect prediction.
    Zhou Y; Pirmann S; Lauschke VM
    Pharmacogenomics J; 2024 May; 24(3):17. PubMed ID: 38802404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Precision medicine in diabetes prevention, classification and management.
    Xie F; Chan JC; Ma RC
    J Diabetes Investig; 2018 Sep; 9(5):998-1015. PubMed ID: 29499103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacomicrobiomics: a novel route towards personalized medicine?
    Doestzada M; Vila AV; Zhernakova A; Koonen DPY; Weersma RK; Touw DJ; Kuipers F; Wijmenga C; Fu J
    Protein Cell; 2018 May; 9(5):432-445. PubMed ID: 29705929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of treatment outcomes in psychiatry--where do we stand ?
    McMahon FJ
    Dialogues Clin Neurosci; 2014 Dec; 16(4):455-64. PubMed ID: 25733951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Introduction to the Theme "Pharmacological Individuality: New Insights and Strategies for Personalized and Precise Drug Treatment".
    Meyer UA; Amara SG; Blaschke TF; Insel PA
    Annu Rev Pharmacol Toxicol; 2024 Jan; 64():27-31. PubMed ID: 37816308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Comprehensive Review: Personalized Medicine for Rare Disease Cancer Treatment.
    Rajput DS; Gupta N; Singh S; Sharma B
    Zhongguo Ying Yong Sheng Li Xue Za Zhi; 2023 Dec; 39():e20230008. PubMed ID: 38830754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of magnetic resonance imaging in pharmacogenomics.
    Viviani R; Lehmann ML; Stingl JC
    Br J Clin Pharmacol; 2014 Apr; 77(4):684-94. PubMed ID: 23802603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The miRNA-drug resistance connection: a new era of personalized medicine using noncoding RNA begins.
    Mishra PJ
    Pharmacogenomics; 2012 Sep; 13(12):1321-4. PubMed ID: 22966880
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.